Patented Medicine Prices Review Board Departmental Results Report 2022-23

The Patented Medicine Prices Review Board's 2022–23 Departmental Results Report measures the department's performance against its stated plans and priorities. It was published by the Patented Medicine Prices Review Board Canada and last updated on April 16, 2026. The report is available in HTML format under the OGL-CA-2.0 license.

Use Cases

• Analyze government agency performance based on reported departmental results.
• Benchmark regulatory outcomes against planned priorities mentioned in the description.
• Study the operational reporting framework of a pharmaceutical price review board.

Strengths

• Report is published by the authoritative regulatory body, the Patented Medicine Prices Review Board Canada.
• Data is licensed under the open OGL-CA-2.0 license for reuse.
• Last updated timestamp of 2026-04-16 is provided.

Limitations

• Row count and column-level documentation are absent; field semantics must be inferred after download.
• Data may reflect temporal and institutional bias inherent to a single government agency report.
• Description metadata is limited; actual data quality requires manual inspection after download.

Provenance

Source

Patented Medicine Prices Review Board Canada | Conseil d'examen du prix des médicaments brevetés Canada

Time Range

2022-2023

Freshness

Last updated 2026-04-16 19:27:00.037851; freshness should be verified.

Geography

Canada